Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Blood Triglyceride

A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Blood Triglyceride

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03079648

Enrollment

100

Registered

2017-03-14

Start date

2017-03-02

Completion date

2018-04-06

Last updated

2019-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemias

Keywords

Angelica gigas N. extract, Hyperlipidemia, Clinical Trial

Brief summary

This study was conducted to investigate the effects of daily supplementation of Angelica gigas N. extract on improvement of Blood Triglyceride.

Detailed description

This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. Twenty subjects were randomly divided into Angelica gigas N. extract or a placebo group. Fasting triglyceride profiles before and after the intervention.

Interventions

DIETARY_SUPPLEMENTAngelica gigas N. extract

capsules (2cap/d, 1,000mg/d) for 12 weeks.

DIETARY_SUPPLEMENTPlacebo

Placebo for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 19-80 years with Triglyceride 130-200 mg/dL

Exclusion criteria

* Lipid lowering agent within past 6 months * Severe cardiovascular disease(Mvocardial infarction, Stroke, etc) * Renal disease(Heredity hyperlipidemia, Acute/Chronic renal failure, Nephrotic syndrome, etc) * Cancer, Respiratory organ disease(Asthma, Chronic obstructive pulmonary disease) * Autoimmune disease * Diabetes mellitus * Allergic or hypersensitive to any of the ingredients in the test products * History of disease that could interfere with the test products or impede their absorption * Under antipsychotic drugs therapy within past 2 months * History of alcohol or substance abuse * Participation in any other clinical trials within past 2 months * Laboratory test by show the following results * aspartate aminotransferase, alanine aminotransferase \> Reference range upper limit treble * Serum Creatinine \> 2.0 mg/dl * Pregnancy or breast feeding * Not Contraception(except: Surgery for female infertility)

Design outcomes

Primary

Measure	Time frame	Description
Changes of Triglyceride	12 weeks	Changes of triglyceride were assessed before and after the intervention

Secondary

Measure	Time frame	Description
Changes of Lipid profile	12 weeks	Changes of Lipid profile were assessed before and after the intervention
Changes of Arteriosclerosis index	12 weeks	Changes of Arteriosclerosis index were assessed before and after the intervention

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026